In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020-2021 : a multicenter study
© 2023. The Author(s)..
Resistance of Acinetobacter baumannii to multiple clinically important antimicrobials has increased to very high rates in Greece, rendering most of them obsolete. The aim of this study was to determine the molecular epidemiology and susceptibilities of A. baumannii isolates collected from different hospitals across Greece. Single-patient A. baumannii strains isolated from blood cultures (n = 271), from 19 hospitals, in a 6-month period (November 2020-April 2021) were subjected to minimum inhibitory concentration determination and molecular testing for carbapenemase, 16S rRNA methyltransferase and mcr gene detection and epidemiological evaluation. 98.9% of all isolates produced carbapenemase OXA-23. The vast majority (91.8%) of OXA-23 producers harbored the armA and were assigned mainly (94.3%) to sequence group G1, corresponding to IC II. Apramycin (EBL-1003) was the most active agent inhibiting 100% of the isolates at ≤16 mg/L, followed by cefiderocol which was active against at least 86% of them. Minocycline, colistin and ampicillin-sulbactam exhibited only sparse activity (S <19%), while eravacycline was 8- and 2-fold more active than minocycline and tigecycline respectively, by comparison of their MIC50/90 values. OXA-23-ArmA producing A. baumannii of international clone II appears to be the prevailing epidemiological type of this organism in Greece. Cefiderocol could provide a useful alternative for difficult to treat Gram-negative infections, while apramycin (EBL-1003), the structurally unique aminoglycoside currently in clinical development, may represent a highly promising agent against multi-drug resistant A. baumanni infections, due to its high susceptibility rates and low toxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 42(2023), 7 vom: 18. Juli, Seite 843-852 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Galani, Irene [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.06.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10096-023-04616-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356369323 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356369323 | ||
| 003 | DE-627 | ||
| 005 | 20231227131234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-023-04616-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM356369323 | ||
| 035 | |a (NLM)37133639 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galani, Irene |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020-2021 |b a multicenter study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.06.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Resistance of Acinetobacter baumannii to multiple clinically important antimicrobials has increased to very high rates in Greece, rendering most of them obsolete. The aim of this study was to determine the molecular epidemiology and susceptibilities of A. baumannii isolates collected from different hospitals across Greece. Single-patient A. baumannii strains isolated from blood cultures (n = 271), from 19 hospitals, in a 6-month period (November 2020-April 2021) were subjected to minimum inhibitory concentration determination and molecular testing for carbapenemase, 16S rRNA methyltransferase and mcr gene detection and epidemiological evaluation. 98.9% of all isolates produced carbapenemase OXA-23. The vast majority (91.8%) of OXA-23 producers harbored the armA and were assigned mainly (94.3%) to sequence group G1, corresponding to IC II. Apramycin (EBL-1003) was the most active agent inhibiting 100% of the isolates at ≤16 mg/L, followed by cefiderocol which was active against at least 86% of them. Minocycline, colistin and ampicillin-sulbactam exhibited only sparse activity (S <19%), while eravacycline was 8- and 2-fold more active than minocycline and tigecycline respectively, by comparison of their MIC50/90 values. OXA-23-ArmA producing A. baumannii of international clone II appears to be the prevailing epidemiological type of this organism in Greece. Cefiderocol could provide a useful alternative for difficult to treat Gram-negative infections, while apramycin (EBL-1003), the structurally unique aminoglycoside currently in clinical development, may represent a highly promising agent against multi-drug resistant A. baumanni infections, due to its high susceptibility rates and low toxicity | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acinetobacter baumannii | |
| 650 | 4 | |a Apramycin | |
| 650 | 4 | |a ArmA | |
| 650 | 4 | |a Cefiderocol | |
| 650 | 4 | |a Eravacycline | |
| 650 | 4 | |a IC II | |
| 650 | 4 | |a OXA-23 | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a omadacycline |2 NLM | |
| 650 | 7 | |a 090IP5RV8F |2 NLM | |
| 650 | 7 | |a eravacycline |2 NLM | |
| 650 | 7 | |a 07896928ZC |2 NLM | |
| 650 | 7 | |a apramycin |2 NLM | |
| 650 | 7 | |a 388K3TR36Z |2 NLM | |
| 650 | 7 | |a Minocycline |2 NLM | |
| 650 | 7 | |a FYY3R43WGO |2 NLM | |
| 650 | 7 | |a RNA, Ribosomal, 16S |2 NLM | |
| 700 | 1 | |a Papoutsaki, Vassiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Karaiskos, Ilias |e verfasserin |4 aut | |
| 700 | 1 | |a Moustakas, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Galani, Lamprini |e verfasserin |4 aut | |
| 700 | 1 | |a Maraki, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Mavromanolaki, Viktoria Eirini |e verfasserin |4 aut | |
| 700 | 1 | |a Legga, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Fountoulis, Kimon |e verfasserin |4 aut | |
| 700 | 1 | |a Platsouka, Evangelia D |e verfasserin |4 aut | |
| 700 | 1 | |a Giannopoulou, Panagiota |e verfasserin |4 aut | |
| 700 | 1 | |a Papadogeorgaki, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Damala, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Chinou, Efrosini |e verfasserin |4 aut | |
| 700 | 1 | |a Pasxali, Aggeliki |e verfasserin |4 aut | |
| 700 | 1 | |a Deliolanis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Vagiakou, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Petinaki, Efthymia |e verfasserin |4 aut | |
| 700 | 1 | |a Chli, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Vagdatli, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Kazila, Polyzo |e verfasserin |4 aut | |
| 700 | 1 | |a Papaioannou, Vassiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Kontopoulou, Konstantina |e verfasserin |4 aut | |
| 700 | 1 | |a Ferke, Atalia Noemi |e verfasserin |4 aut | |
| 700 | 1 | |a Moraitou, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Antoniadou, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Giamarellou, Helen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 42(2023), 7 vom: 18. Juli, Seite 843-852 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:7 |g day:18 |g month:07 |g pages:843-852 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-023-04616-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 7 |b 18 |c 07 |h 843-852 | ||